|New Threads Only:|
|New Threads & Replies:|
Forum List » Value Ideas and Strategies|
Share and discuss value investing ideas and investing strategies.
Growth Spotlight: Novartis AG
Posted by: investingdaily (IP Logged)
Date: June 21, 2012 11:46PM
Swiss drugmaker Novartis AG (NVS) in April reported first-quarter 2012 earnings per share (EPS) of $1.27, down from the $1.4 posted a year earlier. First-quarter revenue fell to $13.7 billion from last year’s $14 billion. Earnings dropped 18 percent, to $2.3 billion.
Novartis’ revenue was hit by generic drug competition and manufacturing problems at its factory in Lincoln, Nebraska. This year, Novartis faces additional challenges to revenue, as its top-selling drug Diovan for hypertension loses patent protection.
However, the company isn’t taking patent protection lying down. Its recent $50 billion acquisition of Alcon (ACL), a developer of eye-care products, as well as the launch of new drugs, will help offset any patent losses. The company expects 2012 revenue to be roughly in line with 2011.
Novartis’ portfolio contains plenty of proven, big-selling drugs. The company’s sales of Afinitor, for the treatment of advanced kidney cancer, leaped 60 percent in the first quarter to $143 million; sales of the chronic leukemia drug Tasigna jumped 39 percent to $209 million; and sales of eye drug Lucentis increased 30 percent to $567 million. Moreover, the company’s Gilenya, the first oral treatment approved for multiple sclerosis, continues to capture market share and generated sales of $247 million during the period.
Novartis’ Alcon unit also performed well, racking up a 5 percent increase in revenue to $2.5 billion. On the downside, the company’s Consumer Health segment endured a 20 percent drop in first-quarter sales to $932 million, stemming from the suspension of its troubled Lincoln manufacturing site. However, the company has now resolved these glitches and expects to resume full-throttle production by mid-year.
Novartis continues to funnel substantial resources into developing new product lines. The company spent $9.6 billion in research and development (R&D) last year, about 16.4 percent of revenue. This R&D commitment is paying off with a deep bench of potentially profitable products. The company recently announced plans to make regulatory filings for more than 60 new drug treatments through 2015.
Novartis also reached an agreement to acquire the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co, as part of a strategic push into the fast-growing and potentially vast vaccine market in China.
In addition to its growth prospects, Novartis sports an attractive dividend yield of 4.49 percent. The company’s earnings yield is around 7 percent, which means it pays out nearly 65 percent of earnings as dividends
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.